Nanogen Hopes to Establish European Beachhead Through $10M Acquisition of Amplimedical Dx Unit | GenomeWeb

Continuing a trend of regular acquisitions, Nanogen last week set its eyes on the European market by announcing plans to acquire Amplimedical, the diagnostics subsidiary of Italian firm Amplifon, for €8.1 million ($10 million).

Following the acquisition, planned to close May 1, the company will move its existing Dutch office into the newly acquired Italian base to form a new subsidiary called Nanogen Advanced Diagnostics, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.